Hepion pharmaceuticals completes final patient recruitment in phase 2a 'ambition' clinical trial of crv431 for the treatment of advanced nash

Edison, n.j., may 06, 2021 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("nash"), today announced that it has completed recruitment for its phase 2a ‘ambition' clinical trial, with all nash patients in the 225 mg crv431 dosing cohort now enrolled.
HEPA Ratings Summary
HEPA Quant Ranking